CENTRAL SEC. DL 1

Central Securities Corporation consistently outperforms the S&P 500 Total Return Index, making it a strong choice for long-term capital growth, despite its lower yield compared to peers. The fund's value-oriented strategy with limited exposure to the technology sector has helped it perform well, especially during periods of market volatility. The technology sector was responsible for much of the year-to-date market decline, so the fact that this fund invests elsewhere, could be very appealing right now.» Mehr auf seekingalpha.com

$737 million in fourth quarter and $2.2 billion in full year global product net sales Received positive CHMP recommendation for VYVGART pre-filled syringe for gMG, enabling launch in the EU; FDA PDUFA (gMG and CIDP) on track for April 10 10 Phase 3 and 10 Phase 2 studies across pipeline ongoing in 2025, positioning for next wave of growth Recognized one-time tax benefit of $725 million related to previously unrecognized deferred tax assets Management to host conference call today at 2:30 PM CET (8:30 AM ET) February 27, 2025 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today reported financial results for the full year 2024 and provided a fourth quarter business update. "In 2024, we significantly expanded our global patient reach with VYVGART, surpassing 10,000 patients across three indications,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.» Mehr auf globenewswire.com

Invitation to Q4 2024 Presentation 27 February BW Offshore will release its Q4 2024 results on Thursday 27 February at 07:30 CET. A conference call followed by Q&A will be hosted by CEO Marco Beenen and CFO Ståle Andreassen the same day at 09:00 CET.» Mehr auf globenewswire.com